Decade is an Applied AI Lab rethinking cancer from first principles.

Cancer medicines typically take a decade to create but often provide only a few incremental months of survival. Our goal is to create medicines in months that help patients live for decades.

Decade is starting from three ideas:

  1. Cancer evolves. Cancer cells evade the immune system, adapt to treatment and compete with each other. This is the main reason treatment fails.
  2. AI enables speed. Sequencing lets us see cancers evolve. With AI, we will be able to design medicines to keep pace with disease.
  3. The clinic is the eval. Patient data are the readout that matters and clinical cycle time sets the pace of learning. We prioritize methods that enable rapid clinical feedback.

Our strategy is not to use AI to model biology for its own sake, but to engineer toward the endpoints patients care about.

Team

Founders

  • Devin Scannell

    Devin Scannell, Ph.D.

    Co-Founder and CEO

    Devin has spent his career integrating AI and biology or developing cancer therapeutics. At Flagship Pioneering, he built companies that use AI and automation to unlock new biology at scale. At Zymergen, a pioneer in applying AI/ML to biology, he led the therapeutics business which he focused on cancer and also led partnerships with Genentech and Boehringer Ingelheim. Earlier he advised pharma and biotech clients across the oncology landscape, including cancer vaccines, ADCs, and radiopharmaceuticals. He has extensive M&A experience and has raised capital from pre-seed to IPO.

    Devin received a Ph.D. in computational genomics from Trinity College Dublin.

  • Brian Naughton

    Brian Naughton, Ph.D.

    Co-Founder and CTO

    Brian combines many of the disciplines at the core of Decade: genomics, machine learning, AI protein design, and oncology therapeutics. He co-founded and served as CTO of Hexagon Bio, a preclinical antibody-drug conjugate (ADC) company focused on oncology and backed by TCG and others. While there, his machine learning team led the search for novel, potent payloads that can overcome cancer resistance. Earlier, Brian was Founding Scientist at 23andMe, where he led the creation of the Personal Genome Service and helped grow the company to over half a million customers. He is a recognized expert on AI protein design.

    Brian received a Ph.D. in biomedical informatics from Stanford University.

Advisors

  • Alex Rubinsteyn

    Alex Rubinsteyn, Ph.D.

    Professor of Genetics and Computational Medicine at the University of North Carolina at Chapel Hill and co-director of the Personalized Immunotherapy Research Lab

    Prof. Rubinsteyn is a principal developer of MHCflurry, the open-source model that predicts which tumor peptides are displayed on the surface of cells for immune surveillance. At Mount Sinai, he helped start three personalized cancer vaccine trials. In September 2026, the OpenAI Foundation awarded $40 million to UNC Lineberger for work he co-leads to develop open datasets and AI models that select better targets for individualized medicines.

    Prof. Rubinsteyn received a Ph.D. in computer science from New York University.

  • Martin Pačesa

    Martin Pačesa, Ph.D.

    Assistant Professor of Advanced Biological Therapeutics in the Department of Pharmacology at the University of Zurich

    Prof. Pačesa develops methodologies for the study and design of biomolecular interactions for research and therapeutic use. He is the lead developer of BindCraft, an open-source deep learning pipeline for de novo protein binder design, published in Nature. BindCraft is now one of the most widely used tools for binder design, and his lab recently released BindCraft2, which extends design to peptides, antibodies, and VHHs. His honors include the Peter und Traudl Engelhorn Research Prize 2026, the 2026 Eppendorf Award for Young European Investigators and a European Research Council Starting Grant.

    Prof. Pačesa received a Ph.D. in biochemistry from the University of Zurich.

  • Jason S. Lewis

    Jason S. Lewis, Ph.D.

    Emily Tow Chair at Memorial Sloan Kettering Cancer Center (MSK), Deputy Director of the Sloan Kettering Institute and member of the Molecular Pharmacology Program

    Prof. Lewis leads a molecular imaging research program that develops radiopharmaceuticals and multimodality imaging agents and moves them into the clinic. He has authored more than 380 publications, has served as president of both the World Molecular Imaging Society and the Society for Radiopharmaceutical Sciences, and was elected to the National Academy of Inventors in 2025. He is the incoming president of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). His honors include the SNMMI Saul Hertz Award, the WMIS Gold Medal, and the ACS Seaborg Award.

    Prof. Lewis received a Ph.D. in biochemistry from the University of Kent.

  • Alejandro Bertolet

    Alejandro Bertolet, Ph.D.

    Assistant Professor of Radiology at Harvard Medical School and Director of Radiopharmaceutical Dosimetry at Massachusetts General Hospital (MGH)

    Prof. Bertolet's research aims to make radiopharmaceutical therapy precise and personal, guided by the radiation dose that each patient actually receives. His team has developed multiscale dosimetry methods that trace dose from the whole patient down to single cells and DNA. He has authored more than 50 publications. His honors include the Jack Fowler Award from the Radiation Research Society and the John D. Boice, Jr. Young Investigator Award from the NCRP.

    Prof. Bertolet received a Ph.D. in radiation biophysics from the Universidad de Sevilla.

  • Per Greisen

    Per Greisen, Ph.D.

    Chief Scientist of AI Biology at BioMap

    Dr. Greisen is an expert in computational protein design, focusing on antibody developability: the properties a protein needs to succeed in the clinic and in manufacturing. As Vice President for Computational Drug Design at Novo Nordisk, he contributed to many programs, including the complex bispecifics denecimig and sutacimig, both now in late-stage clinical development.

    Dr. Greisen received a Ph.D. in physics from the Technical University of Denmark and completed postdoctoral training in David Baker's lab at the University of Washington.

Investors

In addition to our institutional investors, we are grateful for investments from Sid Sijbrandij, Anne Wojcicki and Georges Harik.